Conflict of interest
MM
BLOOD
YM served as a consultant for Sanofi K.K. and Zenyakukogyo Co., Ltd., has participated in advisory boards for Sanofi K.K., and received research funding from Sanofi K.K. KI received honoraria from Celgene Co., Ltd., Bristol-Myers Squibb K.K., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Otuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Novartis Pharma K.K, Meiji Seika Pharma Co. Ltd., Ono Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Nippon Shinyaku Co., Ltd., and AstraZeneca K.K. SI received honoraria from Sanofi K.K., AstraZeneca K.K, and Chugai Pharmaceutical Co., Ltd. TM served on advisory boards for Takeda Pharmaceutical Co. Ltd. (Baxalta/Shire), Bayer Yakuhin, Ltd., Novo Nordisk Pharma Ltd., Chugai Pharmaceutical Co., Ltd., and Pfizer Inc., received educational and investigational support from Chugai Pharmaceutical Co., Ltd. and Novo Nordisk Pharma Ltd., and received honoraria from Takeda Pharmaceutical Co. Ltd. (Shire), Bayer Yakuhin, Ltd., Sanofi K.K. (Bioverative), Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Japan Blood Products Organization, KM Biologics Co., Ltd., Kyowa Kirin Co., Ltd., Nichiyaku, Novo Nordisk Pharma Ltd., Octapharma AG, and Sysmex Corporation. MM received honoraria from Asahi Kasei Pharma Corporation, Chugai Pharmaceutical Co., Ltd., and Alexion Pharma Inc., has served as a consultant for Sanofi K.K., Takeda Pharmaceutical Co. Ltd., and Alexion Pharma Inc., received research funding from Asahi Kasei Pharma Corporation and Chugai Pharmaceutical Co., Ltd., and received patents and royalties from Alfesa Pharma Corporation. YH, ST, HM, and TT are currently employed by Sanofi K.K. HU, YU, AY, SF, YO, HA, KN, and KS declare that they have no conflicts of interest.